Quantification of perioperative changes in von Willebrand factor and factor VIII during elective orthopaedic surgery in normal individuals

Haemophilia

Volumn 19, Issue 5, 2013, Pages 758-764

  Kahlon, A ^a   Grabell, J ^a   Tuttle, A ^a   Engen, D ^a   Hopman, W ^b   Lillicrap, D ^b   James, P ^a  

^a KINGSTON GENERAL HOSPITAL   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Factor VIII; Surgery; Von Willebrand factor

Indexed keywords

BLOOD CLOTTING FACTOR 8; VON WILLEBRAND FACTOR;

ADULT; AGED; ANESTHESIA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; FEMALE; HUMAN; LABORATORY TEST; MALE; MOLECULAR WEIGHT; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; SURGICAL STRESS; VON WILLEBRAND DISEASE;

FACTOR VIII; SURGERY; VON WILLEBRAND FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; FACTOR VIII; FEMALE; HUMANS; MALE; MIDDLE AGED; VON WILLEBRAND FACTOR;

EID: 84883053558     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12185     Document Type: Article

References (28)

1. Nichols WL, Hultin MB, James AH et al. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Hemophilia 2008; 14(2): 171-232.
2. Bowman M, Hopman WM, Rapson D, Lilicrap D, James P. The prevalence of symptomatic von Willebrand disease in primary care practice. J Thromb Haemost 2010; 8(1): 213-6.
3. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987; 69: 454-9.
4. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von Willebrand disease in children: a multiethnic study. J Pediatr 1993; 123: 893-8.
5. Michiels JJ, van Vliet HH, Berneman Z et al. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients with von Willebrand disease type 1, 2, and 3. Clin Appl Thromb Hemost 2007; 13(1): 14-34.
6. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97(7): 1915-9.
7. Mannucci PM. Treatment of von Willebrand's Disease. N Engl J Med 2004; 351(7): 638-94.
8. Mannucci PM. Venous thromboembolism in von Willebrand disease. Thromb Haemost 2002; 88(3): 378-9.
9. Casonato A, Pontara E, Bertomoro A, Cattini MD, Soldera C, Girolami A. Fainting induces an acute increase in the concentration of plasma factor VIII and von Willebrand factor. Haematologica 2003; 88(6): 688-93.
10. Zezos P, Papaioannou G, Nikoaidis N, Vassiladis T, Giouleme O, Evgenidis N. Elevated plasma von Willebrand factor levels in patients with active ulcerative colitis reflect endothelial perturbation due to systemic inflammation. World J Gastroenterol 2005; 11(48): 7639-45.
11. Lippi G, Franchini M, Targher G, Poli G, Guidi GC. The significance of evaluating conventional inflammatory markers in von Willebrand factor measurement. Clin Chim Acta 2007; 381(2): 167-70.
12. Claus RA, Bockmeyer CL, Sossdorf M, Losche W, Hilberg T. Physical stress as a model to study variations in ADAMTS-13 activity, von Willebrand factor level and platelet activation. J Thromb Haemost 2006; 4(4): 902-5.
13. Franchini M. Surgical prophylaxis in von Willedbrand's disease: a difficult balance to manage. Blood Transfus 2008; 6(suppl 2): s33-8.
14. Clinical and Laboratory Standards Institute (formerly NCCLS). Assays of von Willebrand Factor Antigen and Ristocetin Cofactor Activity. Approved Guideline Document H51-A 22, Number 20. 2002. 1991.
15. Hardisty RM, Macpherson JC. A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diath Haemorrh 1962; 7: 215-28.
16. Budde U, Schneppenheim R, Plendl H, Dent J, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 1990; 63: 312-5.
17. Ruggeri ZM, Zimmerman TS. Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 1980; 65: 1318-25.
18. Hughes SF, Hendricks BD, Edwards DR, Maclean KM, Bastawrous SS, Middleton JF. Total hip and knee replacement surgery results in changes in leukocyte and endothelial markers. J Inflamm (Lond) 2010; 7: 2.
19. Schols SEM, Lance MD, Feijge MAH et al. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thromb Haemost 2010; 103(2): 318-28.
20. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM. von Willebrand factor/factor VIII concentrate (Haemate P) dosing based on pharmacokinetics: a prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-30.
21. Mannuci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 2002; 99: 450-6.
22. Berntorp E, Archey W, Auerswald G et al. A systematic overview of the first pasteurized VVWF/FVIII medicinal product, Haemate P/Humate-P: history and clinical performance. Eur J Haematol 2008; 80(s70): 3-35.
23. Tagariello G, Iorio A, Santagostino E et al. Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders. Blood 2009; 114: 779-84.
24. Hoffman M, Monroe DM. Wound healing in haemophilia - breaking the vicious cycle. Haemophilia 2010; 16(Suppl. 3): 13-8.
25. Gill JC, Shapiro A, Valentino LA et al. von Willebrand factor/factor VIII concentrate (Humate-P) for management of elective surgery in adults and children with von Willebrand disease. Haemophilia 2011; 17: 895-905.
26. Monroe DM, Hoffman M. The clotting system - a major player in wound healing. Haemophilia 2012; 18(Suppl 5): 11-6.
27. Wells PS, Langois NJ, Webster MA, Jaffey J, Anderson JA. Elevated factor VIII is a risk factor for idiopathic venous thromboembolism in Canada - is it necessary to define a new upper reference range for factor VIII? Thromb Haemost 2005; 93: 842-6.
28. Coppola A, Franchini M, Makris M, Santagostino E, Di Minno S, Mannucci PM. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia 2012; 18: e173-87.